Theravance Biopharma, Inc.
TBPH- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001583107
In the last 90 days, Theravance Biopharma, Inc. insiders filed 0 open-market purchases and 2 sales; 179 institutions reported holding it in 13F filings for Q2 2026, worth $817.5M in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding Theravance Biopharma, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Of which not filed for Q1 2024 | Q1 2024 | Change |
|---|---|---|---|---|
| Holders | 118 | 1 | 121 | +4 |
| Shares | 48.8M | 12.6K | 48.0M | −822.2K (−1.7%) |
| Value | $548.7M | $141.4K | $430.6M | −$118.0M (−21.5%) |
1 institution that held it in Q4 2023 haven't filed for Q1 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (19)
Institutions that held Theravance Biopharma, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Camber Capital Management LP | 1,000,000 | $8.97M | 0.31% |
| Marshall Wace, LLP | 162,073 | $1.45M | 0.00% |
| ExodusPoint Capital Management, LP | 80,755 | $724.0K | 0.01% |
| Bank of Montreal | 66,436 | $599.3K | 0.00% |
| Petrus Trust Company, LTA | 62,028 | $556.4K | 0.05% |
| Jump Financial, LLC | 43,447 | $389.7K | 0.01% |
| Assenagon Asset Management S.A. | 40,166 | $360.3K | 0.00% |
| Balyasny Asset Management LLC | 31,285 | $280.6K | 0.00% |
| Graham Capital Management, L.P. | 16,353 | $146.7K | 0.00% |
| Campbell & CO Investment Adviser LLC | 15,502 | $139.1K | 0.01% |
| Point72 Asia (Singapore) Pte. Ltd. | 11,806 | $105.9K | 0.03% |
| Atom Investors LP | 11,576 | $103.8K | 0.01% |
| Catalyst Funds Management Pty Ltd | 11,410 | $102.3K | 0.03% |
| Cubist Systematic Strategies, LLC | 5,834 | $52.3K | 0.00% |
| Aquatic Capital Management LLC | 1,900 | $17.0K | 0.00% |
| Steward Partners Investment Advisory, LLC | 1,500 | $13.5K | 0.00% |
| Riggs Asset Managment Co. Inc. | 117 | $1.05K | 0.00% |
| Huntington National Bank | 88 | $789 | 0.00% |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 13 | $116 | 0.00% |
Sold out (15)
Institutions that held Theravance Biopharma, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Highbridge Capital Management LLC | 166,234 | $1.87M |
| Gsa Capital Partners LLP | 77,070 | $866.0K |
| Susquehanna International Group, LLP | 53,263 | $598.7K |
| Squarepoint Ops LLC | 52,054 | $585.1K |
| Occudo Quantitative Strategies LP | 49,517 | $556.6K |
| Two Sigma Investments, LP | 38,939 | $437.7K |
| Susquehanna Portfolio Strategies, LLC | 13,317 | $149.7K |
| Bleakley Financial Group, LLC | 12,584 | $141.4K |
| Teacher Retirement System of Texas | 10,100 | $114.0K |
| Natixis | 2,000 | $22.5K |
| Fortitude Family Office, LLC | 441 | $4.96K |
| Lindbrook Capital, LLC | 280 | $3.15K |
| Allworth Financial LP | 178 | $2.00K |
| Massmutual Trust Co FSB | 42 | $472 |
| JNBA Financial Advisors | 1 | $12 |
Not filed for Q1 2024 yet (1)
Institutions that held Theravance Biopharma, Inc. at the end of Q4 2023 and haven't filed a 13F for Q1 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Sawtooth Solutions, LLC | 12,584 | $141.4K |